Clinical data | |
---|---|
Trade names | Duratocin, Pabal, Lonactene, others |
Other names | (2-O-Methyltyrosine)deamino-1-carbaoxytocin; Deamino-2-O-methyltyrosine-1-carbaoxytocin; 1-Butanoic acid-2-(O-methy-L-tyrosine)-1-carbaoxytocin; 1-butyric acid-2-[3-(4-methoxyphenyl)-L-alanine]oxytocin |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Routes of administration | Intravenous, intramuscular |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 80% (IM) |
Elimination half-life | 85–100 minutes[1] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.048.450 |
Chemical and physical data | |
Formula | C45H69N11O12S |
Molar mass | 988.17 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Carbetocin, sold under the brand names Pabal among others, is a medication used to prevent excessive bleeding after childbirth, particularly following Cesarean section.[2] It appears to work as well as oxytocin.[3] Due to it being less economical than other options, use is not recommended by NHS Scotland.[2] It is given by injection into a vein or muscle.[3]
Side effects differ little from that of no treatment or placebo.[3] Use is not recommended in people with epilepsy or eclampsia.[2] Carbetocin is a manufactured long acting form of oxytocin.[3] It works by activating the oxytocin receptor which causes the uterus to contract.[4][3]
Carbetocin was first described in 1974.[5] It was approved for medical use in Canada and the United Kingdom in 1997.[3] It is on the World Health Organization's List of Essential Medicines.[6] It is not available in the United States or Japan.[7][3]